

₽! 2	t- 16			Me	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	ວິດ	Š :	Ę,	₽	45	<u>.</u>	+0	.) 	<b>+</b>	
	Days											2	4	_	
Placebo	Symptoms	0	<del>-</del>	0	0	2	7	0		0	0	က	7.5	0	0
	ID # Syr	87917	63863	92420	61657	43972	71408	81837	10281	87025	53458	37949	47070	58588	19885
	ns Davs														
Active	Symptoms	2	1 01		<del></del>			<del></del>	က	6	4	-		8	2
	# (-	14	59516	26504	44407	85922	33787	98275	77921	59089	940904	24878	82466	10573	89534

	Variable 2	1.15625 2.257291667 16
uming Equal Variances	Variable 1	3.759259259 11.71866097 27 8.257184395 fference 0 2.871225927 0.00322131 1.682878974 0.00644262 2.01954208
Relief of symptoms +-Test: Two-Sample Assuming Equal Variances		Mean Variance Observations Pooled Variance Hypothesized Mean Difference df t Stat t Critical one-tail t Critical one-tail t Critical two-tail

Comparison between test and placebo




Fig. 3